ZN-c3 + Carboplatin + Pegylated liposomal doxorubicin + Paclitaxel + Gemcitabine + Bevacizumab

Phase 1Recruiting

0 views this week 0 watching💤 Quiet

Interest: 26/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Solid Tumor

Conditions

Solid Tumor, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer

Trial Timeline

Oct 26, 2020 → Feb 28, 2027

NCT ID

NCT04516447

About ZN-c3 + Carboplatin + Pegylated liposomal doxorubicin + Paclitaxel + Gemcitabine + Bevacizumab

ZN-c3 + Carboplatin + Pegylated liposomal doxorubicin + Paclitaxel + Gemcitabine + Bevacizumab is a phase 1 stage product being developed by Zentalis Pharmaceuticals for Solid Tumor. The current trial status is recruiting. This product is registered under clinical trial identifier NCT04516447. Target conditions include Solid Tumor, Epithelial Ovarian Cancer, Fallopian Tube Cancer.

What happened to similar drugs?

5 of 13 similar drugs in Solid Tumor were approved

Approved (5) Terminated (2) Active (8)

✅DurvalumabAstraZenecaApproved

✅ARM A : IV iron + epoietin zeta + ARM B: IV iron + epoietin zeta sequence + ARM C : single epoietin zetaRocheApproved

✅denosumab + pamidronateAmgenApproved

✅Sacituzumab Govitecan-hiyGilead SciencesApproved

✅Binimetinib only treatment + Encorafenib only Treatment + Encorafenib & Binimetinib Treatment + Treatment of Encorafenib & Binimetinib & Ribociclib + Treatment of Encorafenib & Binimetinib & CetuximabPfizerApproved

🔄olanzapine plus fosaprepitant-based triple regimen + placebo plus fosaprepitant-based triple regimenSun PharmaceuticalPhase 3

🔄MEDI4736 (Durvalumab) + MEDI4736 (Durvalumab) + TremelimumabAstraZenecaPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04516447	Phase 1	Recruiting	Oct 26, 2020	Feb 28, 2027	Solid Tumor

Competing Products

20 competing products in Solid Tumor

See all competitors

Product	Company	Stage	Hype Score
ALG.APV-527	Alligator Bioscience AB	Phase 1/2	18
ATOR-1017	Alligator Bioscience AB	Phase 1	19
ATOR-1015	Alligator Bioscience AB	Phase 1	19
mRNA-4359	Moderna	Phase 2	0
mRNA-2752 + Durvalumab	AstraZeneca	Phase 1	29
mRNA-4106	Moderna	Phase 1	0
mRNA-4157 + Pembrolizumab + SoC Treatment	Merck	Phase 1	33
mRNA-2416	Moderna	Phase 2	0
E7050	Eisai	Phase 1	29
AFM24 + Atezolizumab 840 MG in 14 ML Injection	Affimed	Phase 1/2	14
EXS21546	Biotrial	Phase 1/2	14
SY-1365 (Part 1) + Carboplatin + Fulvestrant + SY-1365 (Cohort 2) + SY-1365 (Cohort 5) + SY-1365 (Part 2 Single Agent)	Syros Pharmaceuticals	Phase 1	11
BBP-398 + sotorasib	BridgeBio Pharma	Phase 1	18
BBP-398 (Formerly known as IACS-15509)	BridgeBio Pharma	Phase 1	18
SON-1010	Sonnet BioTherapeutics	Phase 1	27
SON-1010	Sonnet BioTherapeutics	Phase 1/2	18
RC220 + Doxorubicin (Adriamycin)	Race Oncology	Phase 1	30
BT1718	Bicycle Therapeutics	Phase 1/2	22
NL-201 + Pembrolizumab Injection [Keytruda]	Neurogene	Phase 1	19
Azenosertib	Zentalis Pharmaceuticals	Phase 1	19